BioHarvest Sciences Inc. (NASDAQ:BHST) Sees Significant Growth in Short Interest

BioHarvest Sciences Inc. (NASDAQ:BHST) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totaling 50,800 shares, a growth of 77.0% from the September 30th total of 28,700 shares. Currently, 0.4% of the company’s shares are short sold. Based on an average daily volume of 55,800 shares, the days-to-cover ratio is presently 0.9 days. Based on an average daily volume of 55,800 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.4% of the company’s shares are short sold.

BioHarvest Sciences Trading Down 8.3%

NASDAQ BHST opened at $8.95 on Friday. The company has a market cap of $146.96 million, a PE ratio of -12.79 and a beta of 0.78. BioHarvest Sciences has a 12 month low of $4.66 and a 12 month high of $12.80. The stock has a 50 day moving average of $9.73 and a 200-day moving average of $7.99.

BioHarvest Sciences (NASDAQ:BHST) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.04). BioHarvest Sciences had a negative net margin of 39.95% and a negative return on equity of 11,357.84%. The business had revenue of $8.52 million during the quarter, compared to the consensus estimate of $8.53 million. BioHarvest Sciences has set its Q3 2025 guidance at EPS. As a group, sell-side analysts predict that BioHarvest Sciences will post -0.8 EPS for the current fiscal year.

Institutional Investors Weigh In On BioHarvest Sciences

A hedge fund recently raised its stake in BioHarvest Sciences stock. True North Advisors LLC grew its position in shares of BioHarvest Sciences Inc. (NASDAQ:BHST) by 7.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 44,391 shares of the company’s stock after buying an additional 3,120 shares during the period. True North Advisors LLC owned approximately 0.27% of BioHarvest Sciences worth $275,000 at the end of the most recent quarter.

Analysts Set New Price Targets

Several brokerages have weighed in on BHST. Wall Street Zen raised BioHarvest Sciences to a “hold” rating in a report on Saturday, October 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of BioHarvest Sciences in a research report on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, BioHarvest Sciences presently has an average rating of “Moderate Buy” and an average price target of $13.67.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.